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Purpose	Measurement of the number of circulating tumor cells (CTCs) in the bloodstream has been shown to
have prognostic significance in treating breast carcinoma. This pilot study was formulated to determine
if stage IV non-small cell lung carcinomas similarly shed malignant cells into the circulation and if their
presence has prognostic significance.
Methods	Patients with stage IV non-small cell lung carcinomas were tested once for CTCs in 7.5 ml of their
blood prior to receiving any treatments. A proprietary blood collection kit produced by Veridex LLC
(Raritan, NJ), which manufactures the instrument that performs the immunomagnetic CELLSEARCH®
CTC assay, was used. Tumor measurements were determined in three dimensions by the same
radiologist using computerized axial tomography. The three-dimensional sum was used to represent
tumor size. Survival from the date of the pretreatment CTC assay was monitored and recorded. Data
were analyzed statistically using NCSS8 statistical software (NCSS LLC, Kaysville, UT).
Results 	Of 19 evaluable patients, 10 had no detectable CTCs. There was no relation between intrapulmonary
primary tumor size and the number of CTCs, nor between tumor size and survival. Survival was not
affected by gender or age at entry into the trial. The mean survival of those with no detectable CTCs
was 536 ± 91.1 days versus 239 ± 96.0 days for those with 1 or more detectable CTCs, a statistically
significant advantage (P=0.034) favoring those without CTCs.
Conclusions	Patients with a CTC score of 0 survived significantly longer than those with a CTC score of ≥ 1. Survival
was not correlated with gender, age or primary tumor size. Recovery of CTCs potentially provides a
noninvasive source of tumor cells for genomic profiling, which may enable development of a custom
treatment plan for the individual patient. Further investigations are warranted and needed. (J Patient
Cent Res Rev. 2016;3:136-141.)
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In the United States, lung cancer is the most common
noncutaneous malignancy in both men and women.
Our ability to treat this disease currently depends on
imaging technologies such as plain film radiography,
computerized axial tomography, magnetic resonance
imaging, radionuclide bone scans and positron
emission tomography (PET).1 These tests tell us about
the location and extent of the disease. While PET

scanning gives limited information regarding disease
activity, the other imaging techniques do not. None of
them determine whether tumor cells are actively being
shed into the bloodstream, which may disseminate the
neoplasm to previously uninvolved areas. In clinical
practice, we monitor changes in the size and number
of sites of disease as indicators that imply control,
response or resistance to a given treatment regimen.
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There are good data supporting the concept that
quantitation of circulating tumor cells (CTCs) can
provide meaningful information regarding the
prognosis and potentially the response of malignancy
to therapy. Cristofanilli et al.2,3 conducted a study of
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177 patients with metastatic breast cancer. They found
that detection of CTCs before the initiation of firstline therapy was highly predictive of progression-free
survival (PFS) and overall survival. There appeared to
be a clear advantage in progression-free and overall
survival favoring those patients with less than 5 CTCs
(per 7.5 ml blood sample as collected) in comparison
to those with 5 or more CTCs. (Unless otherwise
specified, all references herein to the number of
CTCs will be understood to indicate per 7.5 ml blood
sample.) The median progression-free survival of
patients with less than 5 CTCs was 9.5 months versus
4.9 months for those with 5 or more CTCs. Similarly,
the median overall survival was greater than 18
months for those with less than 5 CTCs versus 14.2
months for those with 5 or more CTCs. These results
were highly statistically significant.
Cristofanilli’s group also observed that a decrease
in CTCs was associated with response to therapy
as determined by subsequent conventional imaging
follow-up study. The report does not, however,
indicate the temporal relationship between CTC
reduction and the conventional imaging tool. We do
not know if the change in CTC level precedes tumor
reduction on imaging.3
Reports by others have corroborated Cristofanilli’s
findings as well as offered new insights into tumor
biology. The CTC method offers the prospect of
monitoring nonradiographically measurable breast
cancer.4 Breast cancer patients completing adjuvant
chemotherapy were found to have levels of CTCs
that were statistically the same as pretreatment
values.5 While CTC levels predict survival, serum
tumor markers do not.6 Analysis of CTCs was readily
available in the United States7 when this study was
first proposed in 2007.
Other methods of analyzing CTCs have been
reported from diverse investigators around the
world. Mutant allele-specific amplification analysis
by polymerase chain reaction (PCR) has detected
CTCs in blood and lung samples in rats.8 However,
in that study there was no correlation between the
finding of circulating cell-free DNA and the number
of CTCs. The reverse transcriptase PCR Southern
blot assay has been used to detect CTCs.9 Using
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this technique, 8 of 17 lung carcinoma patients had
evidence of CTCs at the time of diagnosis. After
three cycles of adjuvant chemotherapy, however,
the proportion showing CTCs increased to 12 of 17
patients. This observation is disturbing. Still, it does
not necessarily imply that those CTCs are clonogenic
or even viable. We must consider the possibility that
the chemotherapeutic agents may have mobilized
them into the circulation in a fashion analogous
to mobilization of stem cells for bone marrow
harvesting, which is accomplished by administering
chemotherapy.10 The Rare Event Imaging System,11
the GEN-S hematology analyzer (Beckman Coulter
Inc., Brea, CA)12 and a laser scanning cytometer
(CompuCyte Corp., Westwood, MA)13 are some
other methods that have been studied. The GEN-S
study found a correlation between the number of
CTCs and the weight of the primary tumor as well
as with the number of lung metastases.12
More recently, others have reported the use of
circulating micro-RNA as a marker for lung
cancer.14,15 Cell-free nucleic acids also have been
investigated.14 We initiated our pilot research when it
was not known if stage IV non-small lung carcinoma
would shed quantifiable numbers of tumor cells into
the circulation and whether those results would have
prognostic value.

METHODS

Between January 29, 2010, and October 15, 2012,
one 7.5 ml sample of blood was drawn from 20
consecutive patients diagnosed with stage IV nonsmall cell lung carcinoma after obtaining informed
consent and before initiation of any treatment. The
consent and the study itself were approved by the
local institutional review board. The sample was
drawn using a proprietary collection kit and sent to
Quest Diagnostics/SJC (San Juan Capistrano, CA).
The device used for the CTC count determination was
produced by Veridex LLC (Raritan, NJ).
A malfunction of the CTC counting equipment could
not be remedied before the time window for sample
testing expired on the blood from one patient; as a
result, no assay could be run and the patient was
excluded from analysis. The majority of the patients
in this study had their histologic confirmation of non-
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small cell lung carcinoma obtained via fine needle
aspiration. As such, further histologic typing was not
available and therefore is not reported here. This would
render meaningless attempts at statistical correlations
based upon histology. Likewise, we have not reported
biomarker testing for which adequate tissue was not
available for most of the study population. Thus, 19
patients were available for data analysis.
The CELLSEARCH® CTC Test (CS-CTC, Veridex)
was conducted by our reference laboratory using a
system approved for clinical use by the U.S. Food
and Drug Administration for the identification,
isolation and counting of CTCs. The sensitivity of the
test detects the rare CTC, estimated at 1 per billion
normal blood cells.16 The CS-CTC detects CTCs of
epithelial origin (CD45-, EpCAM+ and cytokeratins
8, 18+ and/or 19+) from a 7.5 mL blood sample with
a high level of sensitivity and specificity. It uses
unique immunomagnetic and fluorescence imaging
technology to provide rapid, precise and reproducible
analysis of CTCs.
The sum of the three largest perpendicular diameters
of the intrathoracic tumor (measured by a radiologist
[E.C.] on computerized axial tomography) was used
in our analysis of tumor size as a RECIST score.
Age (in years), survival (in days from the date of
obtaining the blood sample for this study), CTC
value and tumor size were analyzed using NCSS8, a
Windows-based statistical software program (NCSS
LLC, Kaysville, UT).

Table 1. Age, Sex, CTC Count, Tumor Size and
Survival Data for 19 Evaluable Patients
Age

Sex

CTC
count

Tumor
size (cm)*

Survival
(days)

1

65

F

1

30.6

434

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

60
63
80
56
59
75
59
52
71
56
74
63
76
55
57
64
51

F
M
M
M
M
F
M
M
F
M
M
M
F
M
M
M
F

7
4
1
0
36
127
1
0
0
0
0
0
1
45
0
0
0

20.1
13.2
14.7
12.5
19.0
5.5
5.5
9.1
23.4
15.3
19.3
20.8
14.1
5.4
15.0
15.9
16.4

37
264
67
1,236+
132
260
159
326
236
414
651
793+
759+
40
647+
624+
93

19

82

F

0

11.7

340

Patient #

*Determined by the sum of the three largest perpendicular
diameters.
A “+” symbol after the number of days of survival indicates
the patient was still alive as of Sept. 20, 2013, when data
analysis was performed.

RESULTS

The patients’ data, demographics, CTC count, tumor
size and length of survival are shown in Table 1. A
plus sign after the number of days of survival indicates
that the patient was still alive as of September 20,
2013, when the data analysis was performed.
The mean age of all the patients was 64.1 ± 2.2 years
(range: 51–82 years). The mean survival of the entire
group ± standard error of the entire group was 395.9 ±
73.1 days. Their RECIST scores of tumor size ranged
from 5.4 to 30.6 cm, with a mean of 15.1 ± 1.5 cm.
Ten patients had a CTC score of 0, and 9 had scores of
1 or greater. Mean CTC score was 11.7 ± 7.0.
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Figure 1. A scatterplot of age versus survival is shown.
There was no correlation between age and survival.
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Figure 2. Tumor size (sum of the largest three

Figure 3. A scatter plot of circulating tumor cell (CTC)

There was no statistical difference in survival for men
compared to women (325.3 ± 90.4 days vs. 515.4 ±
118.4 days, respectively, P=0.219). Age at entry into
the study was evaluated and did not correlate with
survival (Figure 1). Primary tumor size, once the
patient had stage IV disease, did not influence survival
(Figure 2). Our pilot study may have lacked adequate
statistical power to detect differences in survival due
to age or gender.

DISCUSSION

perpendicular diameters in centimeters) versus CTC
value is plotted. The size of the dominant mass had no
relationship to the number of circulating tumor cells.

Inspection of a scatterplot of CTC versus survival
suggested there might be a survival advantage
favoring those with a CTC score of 0 versus those
with a CTC score ≥ 1 (Figure 3). Statistical analysis
showed that survival (measured in days ± standard
error of the mean) for those with a CTC score
of 0 was 536 ± 91.1 versus 239 ± 96.0 for those
whose CTC score was greater than or equal to 1.
Tested by the Kruskal-Wallis one-way ANOVA on
ranks-hypotheses, this difference was statistically
significant (P=0.034).
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values versus survival (in days) first suggested that
those patients with a CTC of 0 might have superior
survival as compared to those whose CTC was ≥ 1.

Clearly, some non-small cell lung carcinomas shed
tumor cells into the circulation. Mascalchi et al., using
ScreenCell® methodology, found at least one CTC per 3
ml blood sample and one circulating tumor microembolus
in 65% and 58%, respectively, in their study of 26
consecutive cases of stage III or IV non-small cell lung
carcinoma.17 It is not surprising that different methods of
analysis yield different rates of detection of CTCs. We
found zero CTCs in 10 of our 19 subjects with advanced
disease (52.6%). Okumura et al. found CTCs in the
peripheral blood of 29.4% of patients with resectable
lung carcinoma.18 Our study focused only on patients
with stage IV carcinoma, i.e. unresectable patients.
Size of the tumor did not correlate with the presence or
absence of CTCs. Could the absence of measureable
numbers of CTCs have been due to an artifact caused
by false negatives? If the tumor cells lacked the specific
surface antigens or contained other antigens to which
the test’s reagents were nonreactive, a zero result would
have been obtained. Nonetheless, those of our subjects
with a CTC score of 0 showed superior survival.
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Other investigators before us have used 5 CTCs as
the “break point” for determining low-risk versus
high-risk prognosis. This has been rigorously
determined in breast carcinoma.2-6 We tested our data
comparing those with < 5 CTCs to those with ≥ 5
CTCs. There was no apparent statistical difference
in survival viewed according to those criteria. This
may be a consequence of the small size of our pilot
study or suggest a biologic difference based upon a
different neoplasm in our study (lung) versus those
in Cristofanilli’s group (breast). A larger, more robust
study in lung cancer could potentially answer that
question.
There are indications that the therapy applied may
have an impact on the presence of CTCs in the
peripheral blood. Using an adenoviral probe that
detected the elevated telomerase activity present in
almost all cancer cells but not in normal cells, the
median number of CTCs was assayed in 30 patients
with non-small cell lung carcinoma.19 Median CTC
counts declined from 9.1 CTCs/ml to 0.6 CTCs/ml
post-radiation therapy. Even the type of surgery
appears to have an impact on the number of CTCs.
Huang et al. studied 43 patients who underwent
video-assisted thoracoscopic surgery (VATS) and
36 patients treated by open thoracotomy.20 Blood
samples obtained preoperatively, intraoperatively
and 3 days postoperatively were studied for CTCs
using an immunomagnetic method. The increase in
the number of CTCs comparing pre- to postoperative
assays was statistically significantly lower in
the VATS group than in the open thoracotomy
group (2.18 vs. 9.67, P=0.015). The application of
radiofrequency was evaluated in a study of 9 patients
by Chudasema et al., who found an increase in the
number of CTCs in 7 of the 9.21 The long-term effects
of manipulative and ablative therapeutic procedures
in patients with primary pulmonary neoplasms are
unknown.

CONCLUSIONS

There are circulating tumor cells in persons with stage
IV non-small cell lung carcinoma, and these numbers
can be influenced by the treatment employed. In our
study, the absence of CTCs predicted superior survival
in excess of one year. Further investigations are needed
and indicated.
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Patient-Friendly Recap
• Standard imaging techniques only tell us so
much about the success of a patient’s cancer
treatment.
• Circulating tumor cells (CTCs), cancer cells that
may exist in a patient’s bloodstream, could be
another indicator for prognosis.
• In this pilot study, the authors found that lung
cancer patients without CTCs survive longer
than patients with CTC.
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